| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Doctors and drug companies are also warming to the medical possibilities of ceramides. Later this year, lab testing giant Quest Diagnostics will start to offer the analysis, potentially making it available to many more patients.
Diagnosing Alzheimer’s disease before symptoms develop may soon be as simple as getting a blood test. New blood tests for certain biomarkers show promise, providing physicians an alternative to expensive scans or invasive spinal taps to make a diagnosis. Quest AD-Detect: Introduced by Quest Diagnostics, this blood test also measures beta-amyloid proteins in your blood to determine your risk for developing Alzheimer’s disease. It does not determine if you have any genetic biomarkers for the disease. The test became available in May 2022, with a cost of $500. There is limited coverage by some health plans.
Although automation and artificial intelligence have long been recognized as a way to improve operational efficiency in clinical laboratories, an industry-wide staffing shortage is creating an added motivation to incorporate more technology. At Secaucus-based Quest Diagnostics, it’s just one of many market forces that is shaping the company’s post-pandemic business strategy.
Medical testing center operator Quest Diagnostics Inc. said that it has begun using a highly automated microbiology lab system that leverages AI to analyze samples. CEO Jim Davis mentioned the platform in the company’s earnings call when he was talking about ways in which it’s trying to counter “significant inflation and wage pressures.”
Do you know your blood type? There’s a good chance that you don’t. More Americans know their horoscope sign (66 percent) than their blood type (51 percent), according to a survey published this year by laboratory company Quest.